Red Queen Therapeutics Revenue and Competitors

Red Queen Therapeutics is a clinical-stage company working to deliver important and accessible new treatment options for a broad range of virus-borne illnesses including influenzas, coronaviruses, and other current and emerging pathogens.\n\nCo-founded by Apple Tree Partners (ATP) and biomedical researcher Loren Walensky, M.D., Ph.D., Red Queen is applying its proprietary stapled lipopeptide technology to develop and deliver new treatments for a broad range of viruses, including coronaviruses, influenzas, and other enveloped viruses. The Red Queen platform mechanism of action, fusion inhibition, is a mode of early intervention that can prevent or mitigate viral infection, enabling accelerated viral clearance and avoidance of severe disease.\n\nBecause Red Queen therapies target the highly conserved mechanism of viral fusion, they can be used across entire viral families and their variants. And because Red Queen’s agents do not depend upon immune system activation, they offer instantaneous protection and are particularly suitable for use by immunocompromised people. Red Queen’s stapled lipopeptide therapeutics are designed to be shelf-stable at room temperature and can be formulated and delivered in multiple ways, including topically by nasal spray or\ninhaler, or systematically by injection.